Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan

J. A. Moscow, C. A. Swanson, K. H. Cowan

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

An in vitro model of acquired melphalan resistance was developed by serial incubation of an MCF-7 human breast cancer cell line in increasing concentrations of melphalan. The resulting derivative cell line, MelR MCF-7, was 30-fold resistant to melphalan. Uptake studies demonstrated decreased initial melphalan accumulation in MelR MCF-7 cells. Inverse-reciprocal plots of initial melphalan uptake revealed a 4-fold decrease in the apparent Vmax of MelR MCF-7 compared with WT MCF-7 (516 amol cell-1 min-1 vs 2110 amol cell-1 min-1 respectively) as well as a decrease in the apparent Kt (36 μM vs 70 μM respectively). Two amino acid transporters have previously been identified as melphalan transporters: system L, which is sodium-independent and inhibited by 2-amino-bicyclo[2,2,l]heptane-2-carboxylic acid (BCH), and system ASC which is sodium dependent and unaffected by BCH. At low concentrations of melphalan (3-30 μm), 1mM BCH competition eliminated the differences between the two cell lines, thus implicating an alteration of the system L transporter in the transport defect in the resistant cells. MelR MCF-7 cells were also evaluated for glutathione-mediated detoxification mechanisms associated with melphalan resistance. There was no difference between MelR MCF-7 and WT MCF-7 in glutathione content, glutathione-S-transferase activity and expression of pi class glutathione S-transferase RNA. In addition, buthionine sulfoximine did not reverse melphalan resistance in MelR MCF-7 cells. Therefore, MelR MCF-7 cells provide an in vitro model of transport-mediated melphalan resistance in human breast cancer cells.

Original languageEnglish (US)
Pages (from-to)732-737
Number of pages6
JournalBritish journal of cancer
Volume68
Issue number4
DOIs
StatePublished - Oct 1993

Fingerprint

Melphalan
Breast Neoplasms
Cell Line
MCF-7 Cells
Amino Acid Transport System L
Glutathione
Sodium
Glutathione S-Transferase pi
Buthionine Sulfoximine
Amino Acid Transport Systems
Heptanes
Carboxylic Acids
Glutathione Transferase
RNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan. / Moscow, J. A.; Swanson, C. A.; Cowan, K. H.

In: British journal of cancer, Vol. 68, No. 4, 10.1993, p. 732-737.

Research output: Contribution to journalArticle

@article{1f79523a78e64225af3abb3bfb76c5da,
title = "Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan",
abstract = "An in vitro model of acquired melphalan resistance was developed by serial incubation of an MCF-7 human breast cancer cell line in increasing concentrations of melphalan. The resulting derivative cell line, MelR MCF-7, was 30-fold resistant to melphalan. Uptake studies demonstrated decreased initial melphalan accumulation in MelR MCF-7 cells. Inverse-reciprocal plots of initial melphalan uptake revealed a 4-fold decrease in the apparent Vmax of MelR MCF-7 compared with WT MCF-7 (516 amol cell-1 min-1 vs 2110 amol cell-1 min-1 respectively) as well as a decrease in the apparent Kt (36 μM vs 70 μM respectively). Two amino acid transporters have previously been identified as melphalan transporters: system L, which is sodium-independent and inhibited by 2-amino-bicyclo[2,2,l]heptane-2-carboxylic acid (BCH), and system ASC which is sodium dependent and unaffected by BCH. At low concentrations of melphalan (3-30 μm), 1mM BCH competition eliminated the differences between the two cell lines, thus implicating an alteration of the system L transporter in the transport defect in the resistant cells. MelR MCF-7 cells were also evaluated for glutathione-mediated detoxification mechanisms associated with melphalan resistance. There was no difference between MelR MCF-7 and WT MCF-7 in glutathione content, glutathione-S-transferase activity and expression of pi class glutathione S-transferase RNA. In addition, buthionine sulfoximine did not reverse melphalan resistance in MelR MCF-7 cells. Therefore, MelR MCF-7 cells provide an in vitro model of transport-mediated melphalan resistance in human breast cancer cells.",
author = "Moscow, {J. A.} and Swanson, {C. A.} and Cowan, {K. H.}",
year = "1993",
month = "10",
doi = "10.1038/bjc.1993.419",
language = "English (US)",
volume = "68",
pages = "732--737",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan

AU - Moscow, J. A.

AU - Swanson, C. A.

AU - Cowan, K. H.

PY - 1993/10

Y1 - 1993/10

N2 - An in vitro model of acquired melphalan resistance was developed by serial incubation of an MCF-7 human breast cancer cell line in increasing concentrations of melphalan. The resulting derivative cell line, MelR MCF-7, was 30-fold resistant to melphalan. Uptake studies demonstrated decreased initial melphalan accumulation in MelR MCF-7 cells. Inverse-reciprocal plots of initial melphalan uptake revealed a 4-fold decrease in the apparent Vmax of MelR MCF-7 compared with WT MCF-7 (516 amol cell-1 min-1 vs 2110 amol cell-1 min-1 respectively) as well as a decrease in the apparent Kt (36 μM vs 70 μM respectively). Two amino acid transporters have previously been identified as melphalan transporters: system L, which is sodium-independent and inhibited by 2-amino-bicyclo[2,2,l]heptane-2-carboxylic acid (BCH), and system ASC which is sodium dependent and unaffected by BCH. At low concentrations of melphalan (3-30 μm), 1mM BCH competition eliminated the differences between the two cell lines, thus implicating an alteration of the system L transporter in the transport defect in the resistant cells. MelR MCF-7 cells were also evaluated for glutathione-mediated detoxification mechanisms associated with melphalan resistance. There was no difference between MelR MCF-7 and WT MCF-7 in glutathione content, glutathione-S-transferase activity and expression of pi class glutathione S-transferase RNA. In addition, buthionine sulfoximine did not reverse melphalan resistance in MelR MCF-7 cells. Therefore, MelR MCF-7 cells provide an in vitro model of transport-mediated melphalan resistance in human breast cancer cells.

AB - An in vitro model of acquired melphalan resistance was developed by serial incubation of an MCF-7 human breast cancer cell line in increasing concentrations of melphalan. The resulting derivative cell line, MelR MCF-7, was 30-fold resistant to melphalan. Uptake studies demonstrated decreased initial melphalan accumulation in MelR MCF-7 cells. Inverse-reciprocal plots of initial melphalan uptake revealed a 4-fold decrease in the apparent Vmax of MelR MCF-7 compared with WT MCF-7 (516 amol cell-1 min-1 vs 2110 amol cell-1 min-1 respectively) as well as a decrease in the apparent Kt (36 μM vs 70 μM respectively). Two amino acid transporters have previously been identified as melphalan transporters: system L, which is sodium-independent and inhibited by 2-amino-bicyclo[2,2,l]heptane-2-carboxylic acid (BCH), and system ASC which is sodium dependent and unaffected by BCH. At low concentrations of melphalan (3-30 μm), 1mM BCH competition eliminated the differences between the two cell lines, thus implicating an alteration of the system L transporter in the transport defect in the resistant cells. MelR MCF-7 cells were also evaluated for glutathione-mediated detoxification mechanisms associated with melphalan resistance. There was no difference between MelR MCF-7 and WT MCF-7 in glutathione content, glutathione-S-transferase activity and expression of pi class glutathione S-transferase RNA. In addition, buthionine sulfoximine did not reverse melphalan resistance in MelR MCF-7 cells. Therefore, MelR MCF-7 cells provide an in vitro model of transport-mediated melphalan resistance in human breast cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=0027422392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027422392&partnerID=8YFLogxK

U2 - 10.1038/bjc.1993.419

DO - 10.1038/bjc.1993.419

M3 - Article

C2 - 8398701

AN - SCOPUS:0027422392

VL - 68

SP - 732

EP - 737

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -